Last data update: May 13, 2024. (Total: 46773 publications since 2009)
Records 1-2 (of 2 Records) |
Query Trace: Sawhney H[original query] |
---|
Impact of HLA-B27 and disease status on the gut microbiome of the offspring of ankylosing spondylitis patients
Stoll ML , DeQuattro K , Li Z , Sawhney H , Weiss PF , Nigrovic PA , Wright TB , Schikler K , Edelheit B , Morrow CD , Reveille JD , Brown MA , Gensler LS . Children (Basel) 2022 9 (4) Multiple studies have shown the microbiota to be abnormal in patients with spondyloarthritis (SpA). The purpose of this study was to explore the genetic contributions of these microbiota abnormalities. We analyzed the impact of HLA-B27 on the microbiota of children at risk for SpA and compared the microbiota of HLA-B27+ pediatric offspring of ankylosing spondylitis (AS) patients with that of HLA-B27+ children with SpA. Human DNA was obtained from the offspring for determination of HLA-B27 status and polygenic risk score (PRS). Fecal specimens were collected from both groups for sequencing of the V4 region of the 16S ribosomal RNA gene. Among the offspring of AS patients, there was slight clustering by HLA-B27 status. After adjusting for multiple comparisons, five operational taxonomic units (OTUs) representing three unique taxa distinguished the HLA-B27+ from negative children: Blautia and Coprococcus were lower in the HLA-B27+ offspring, while Faecalibacterium prausnitzii was higher. HLA-B27+ offspring without arthritis were compared to children with treatment-naïve HLA-B27+ SpA. After adjustments, clustering by diagnosis was present. A total of 21 OTUs were significantly associated with diagnosis state, including Bacteroides (higher in SpA patients) and F. prausnitzii (higher in controls). Thus, our data confirmed associations with B. fragilis and F. prausnitzii with juvenile SpA, and also suggest that the mechanism by which HLA-B27 is associated with SpA may not involve alterations of the microbiota. |
Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the Global Burden of Disease Study
Fitzmaurice C , Allen C , Barber RM , Barregard L , Bhutta ZA , Brenner H , Dicker DJ , Chimed-Orchir O , Dandona R , Dandona L , Fleming T , Forouzanfar MH , Hancock J , Hay RJ , Hunter-Merrill R , Huynh C , Hosgood HD , Johnson CO , Jonas JB , Khubchandani J , Kumar GA , Kutz M , Lan Q , Larson HJ , Liang X , Lim SS , Lopez AD , MacIntyre MF , Marczak L , Marquez N , Mokdad AH , Pinho C , Pourmalek F , Salomon JA , Sanabria JR , Sandar L , Sartorius B , Schwartz SM , Shackelford KA , Shibuya K , Stanaway J , Steiner C , Sun J , Takahashi K , Vollset SE , Vos T , Wagner JA , Wang H , Westerman R , Zeeb H , Zoeckler L , Abd-Allah F , Ahmed MB , Alabed S , Alam NK , Aldhahri SF , Alem G , Alemayohu MA , Ali R , Al-Raddadi R , Amare A , Amoako Y , Artaman A , Asayesh H , Atnafu N , Awasthi A , Saleem HB , Barac A , Bedi N , Bensenor I , Berhane A , Bernabe E , Betsu B , Binagwaho A , Boneya D , Campos-Nonato I , Castaneda-Orjuela C , Catala-Lopez F , Chiang P , Chibueze C , Chitheer A , Choi JY , Cowie B , Damtew S , das Neves J , Dey S , Dharmaratne S , Dhillon P , Ding E , Driscoll T , Ekwueme D , Endries AY , Farvid M , Farzadfar F , Fernandes J , Fischer F , GHiwot TT , Gebru A , Gopalani S , Hailu A , Horino M , Horita N , Husseini A , Huybrechts I , Inoue M , Islami F , Jakovljevic M , James S , Javanbakht M , Jee SH , Kasaeian A , Kedir MS , Khader YS , Khang YH , Kim D , Leigh J , Linn S , Lunevicius R , El Razek HM , Malekzadeh R , Malta DC , Marcenes W , Markos D , Melaku YA , Meles KG , Mendoza W , Mengiste DT , Meretoja TJ , Miller TR , Mohammad KA , Mohammadi A , Mohammed S , Moradi-Lakeh M , Nagel G , Nand D , Le Nguyen Q , Nolte S , Ogbo FA , Oladimeji KE , Oren E , Pa M , Park EK , Pereira DM , Plass D , Qorbani M , Radfar A , Rafay A , Rahman M , Rana SM , Soreide K , Satpathy M , Sawhney M , Sepanlou SG , Shaikh MA , She J , Shiue I , Shore HR , Shrime MG , So S , Soneji S , Stathopoulou V , Stroumpoulis K , Sufiyan MB , Sykes BL , Tabares-Seisdedos R , Tadese F , Tedla BA , Tessema GA , Thakur JS , Tran BX , Ukwaja KN , Uzochukwu BS , Vlassov VV , Weiderpass E , Wubshet Terefe M , Yebyo HG , Yimam HH , Yonemoto N , Younis MZ , Yu C , Zaidi Z , Zaki ME , Zenebe ZM , Murray CJ , Naghavi M . JAMA Oncol 2016 3 (4) 524-548 Importance: Cancer is the second leading cause of death worldwide. Current estimates on the burden of cancer are needed for cancer control planning. Objective: To estimate mortality, incidence, years lived with disability (YLDs), years of life lost (YLLs), and disability-adjusted life-years (DALYs) for 32 cancers in 195 countries and territories from 1990 to 2015. Evidence Review: Cancer mortality was estimated using vital registration system data, cancer registry incidence data (transformed to mortality estimates using separately estimated mortality to incidence [MI] ratios), and verbal autopsy data. Cancer incidence was calculated by dividing mortality estimates through the modeled MI ratios. To calculate cancer prevalence, MI ratios were used to model survival. To calculate YLDs, prevalence estimates were multiplied by disability weights. The YLLs were estimated by multiplying age-specific cancer deaths by the reference life expectancy. DALYs were estimated as the sum of YLDs and YLLs. A sociodemographic index (SDI) was created for each location based on income per capita, educational attainment, and fertility. Countries were categorized by SDI quintiles to summarize results. Findings: In 2015, there were 17.5 million cancer cases worldwide and 8.7 million deaths. Between 2005 and 2015, cancer cases increased by 33%, with population aging contributing 16%, population growth 13%, and changes in age-specific rates contributing 4%. For men, the most common cancer globally was prostate cancer (1.6 million cases). Tracheal, bronchus, and lung cancer was the leading cause of cancer deaths and DALYs in men (1.2 million deaths and 25.9 million DALYs). For women, the most common cancer was breast cancer (2.4 million cases). Breast cancer was also the leading cause of cancer deaths and DALYs for women (523000 deaths and 15.1 million DALYs). Overall, cancer caused 208.3 million DALYs worldwide in 2015 for both sexes combined. Between 2005 and 2015, age-standardized incidence rates for all cancers combined increased in 174 of 195 countries or territories. Age-standardized death rates (ASDRs) for all cancers combined decreased within that timeframe in 140 of 195 countries or territories. Countries with an increase in the ASDR due to all cancers were largely located on the African continent. Of all cancers, deaths between 2005 and 2015 decreased significantly for Hodgkin lymphoma (-6.1% [95% uncertainty interval (UI), -10.6% to -1.3%]). The number of deaths also decreased for esophageal cancer, stomach cancer, and chronic myeloid leukemia, although these results were not statistically significant. Conclusion and Relevance: As part of the epidemiological transition, cancer incidence is expected to increase in the future, further straining limited health care resources. Appropriate allocation of resources for cancer prevention, early diagnosis, and curative and palliative care requires detailed knowledge of the local burden of cancer. The GBD 2015 study results demonstrate that progress is possible in the war against cancer. However, the major findings also highlight an unmet need for cancer prevention efforts, including tobacco control, vaccination, and the promotion of physical activity and a healthy diet. |
- Page last reviewed:Feb 1, 2024
- Page last updated:May 13, 2024
- Content source:
- Powered by CDC PHGKB Infrastructure